| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/2162402X.2016.1261242 |
| P8608 | Fatcat ID | release_uk2tjrxjzrh6bjnkzi36hf3wyu |
| P932 | PMC publication ID | 5353942 |
| P698 | PubMed publication ID | 28344869 |
| P50 | author | Paolo Antonio Ascierto | Q89457677 |
| Rolf Kiessling | Q92024154 | ||
| Ester Simeone | Q110644240 | ||
| Maria Wolodarski | Q114522841 | ||
| Rossana Tallerico | Q114523316 | ||
| Cinzia Garofalo | Q114523318 | ||
| Elio Gulletta | Q114523319 | ||
| Mariaelena Capone | Q30505575 | ||
| Sofia Johansson | Q38319849 | ||
| Andrea Anichini | Q38324345 | ||
| Gennaro Ciliberto | Q38800176 | ||
| Francesco Colucci | Q42608618 | ||
| Yago Pico de Coaña | Q56882779 | ||
| Antonio M Grimaldi | Q57071231 | ||
| Domenico Mallardo | Q57649479 | ||
| Ennio Carbone | Q58804014 | ||
| Gabriele Madonna | Q62676303 | ||
| Elina Staaf | Q63677582 | ||
| Costanza M Cristiani | Q63677588 | ||
| Valentina Carannante | Q63677589 | ||
| Rosa Sottile | Q63677591 | ||
| P2093 | author name string | Klas Kärre | |
| Paolo Frumento | |||
| Eleonora Palella | |||
| P2860 | cites work | Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis | Q73572644 |
| Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma | Q24629841 | ||
| Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation | Q24675931 | ||
| CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation | Q24678846 | ||
| Immune Checkpoint Blockade in Cancer Therapy | Q26830509 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Enhancement of antitumor immunity by CTLA-4 blockade | Q28275730 | ||
| CTLA-4 control over Foxp3+ regulatory T cell function | Q29619413 | ||
| Nivolumab and ipilimumab versus ipilimumab in untreated melanoma | Q29620657 | ||
| Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer | Q33418729 | ||
| Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade | Q33714165 | ||
| „Natural” killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell | Q33906475 | ||
| Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes | Q34411539 | ||
| Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients | Q35114206 | ||
| Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity | Q35208414 | ||
| Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients | Q35616397 | ||
| Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota | Q35833921 | ||
| Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9 | Q35876978 | ||
| Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity | Q35909663 | ||
| Biomarkers on melanoma patient T cells associated with ipilimumab treatment | Q36480617 | ||
| The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression | Q36652214 | ||
| NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. | Q37170785 | ||
| Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients | Q37430286 | ||
| Therapeutic applications: natural killer cells in the clinic. | Q38169644 | ||
| Interleukin-15 in the treatment of cancer | Q38264072 | ||
| Investigation of serum proteome alterations in human endometriosis. | Q38469802 | ||
| Immunologic correlates in the course of treatment with immunomodulating antibodies | Q38475103 | ||
| Anchorage independency promoted tumor malignancy of melanoma cells under reattachment through elevated interleukin-8 and CXC chemokine receptor 1 expression | Q38937617 | ||
| Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma | Q38944336 | ||
| The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production | Q39157852 | ||
| Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors | Q39546314 | ||
| Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab | Q40506025 | ||
| Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab | Q40758666 | ||
| Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab | Q40964128 | ||
| Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. | Q42186944 | ||
| Reversal of natural killer cell exhaustion by TIM-3 blockade | Q43180026 | ||
| Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types | Q46537519 | ||
| Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. | Q50980327 | ||
| Increased serum levels of interleukin-15 correlate with negative prognostic factors in extranodal NK/T cell lymphoma. | Q54310181 | ||
| Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. | Q54432520 | ||
| „Natural”︁ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype | Q54628850 | ||
| Orthogonal projections to latent structures (O-PLS) | Q56435041 | ||
| Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo | Q56898738 | ||
| Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma | Q57781473 | ||
| P433 | issue | 2 | |
| P304 | page(s) | e1261242 | |
| P577 | publication date | 2016-12-07 | |
| P1433 | published in | OncoImmunology | Q18026500 |
| P1476 | title | IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients | |
| P478 | volume | 6 |
| Q49884881 | An Uncoupling of Canonical Phenotypic Markers and Functional Potency of Ex Vivo-Expanded Natural Killer Cells. |
| Q64881806 | Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. |
| Q92265378 | Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review |
| Q64095697 | Circulating CD56 NK cells inversely correlate with survival of melanoma patients |
| Q93012736 | Circulating biomarkers predictive of tumor response to cancer immunotherapy |
| Q92854312 | Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response |
| Q101120982 | Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy |
| Q89965774 | NK Cell-Based Immune Checkpoint Inhibition |
| Q41661175 | Natural Killer Cells: Angels and Devils for Immunotherapy |
| Q99558031 | PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates |
| Q90636970 | Rebalancing Immune Homeostasis to Treat Autoimmune Diseases |
| Q92845900 | Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway |
| Q89796270 | Soluble Tim3 detection by time-resolved fluorescence immunoassay and its application in membranous nephropathy |
| Q56889003 | Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells |
| Q90176787 | Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy? |
Search more.